Cargando…
Targeting the signaling in Epstein–Barr virus-associated diseases: mechanism, regulation, and clinical study
Epstein–Barr virus-associated diseases are important global health concerns. As a group I carcinogen, EBV accounts for 1.5% of human malignances, including both epithelial- and lymphatic-originated tumors. Moreover, EBV plays an etiological and pathogenic role in a number of non-neoplastic diseases,...
Autores principales: | Cao, Ya, Xie, Longlong, Shi, Feng, Tang, Min, Li, Yueshuo, Hu, Jianmin, Zhao, Lin, Zhao, Luqing, Yu, Xinfang, Luo, Xiangjian, Liao, Weihua, Bode, Ann M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7801793/ https://www.ncbi.nlm.nih.gov/pubmed/33436584 http://dx.doi.org/10.1038/s41392-020-00376-4 |
Ejemplares similares
-
Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy
por: Hu, Jianmin, et al.
Publicado: (2020) -
Targeting Epstein-Barr virus oncoprotein LMP1-mediated high oxidative stress suppresses EBV lytic reactivation and sensitizes tumors to radiation therapy: Erratum
por: Hu, Jianmin, et al.
Publicado: (2022) -
Wild-type IDH2 contributes to Epstein–Barr virus-dependent metabolic alterations and tumorigenesis
por: Shi, Feng, et al.
Publicado: (2020) -
Epstein-Barr virus encoded latent membrane protein 1 suppresses necroptosis through targeting RIPK1/3 ubiquitination
por: Liu, Xiaolan, et al.
Publicado: (2018) -
Therapies based on targeting Epstein‐Barr virus lytic replication for EBV‐associated malignancies
por: Li, Hongde, et al.
Publicado: (2018)